SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of February 2019
FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrants name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x |
|
Form 40-F o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o |
|
No x |
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82
On February 20, 2019, Fresenius Medical Care AG & Co. KGaA (the Company) issued an Ad-hoc statement announcing it has resolved to repurchase shares of the Company with an aggregate volume of up to one billion Euros via the capital markets over the next two years.
EXHIBITS
Exhibit 99.1 |
|
Ad-hoc statement on the announcement of a share repurchase program issued February 20, 2019. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: February 20, 2019
|
FRESENIUS MEDICAL CARE AG & Co. KGaA, | ||
|
a partnership limited by shares, represented by: | ||
|
| ||
|
FRESENIUS MEDICAL CARE MANAGEMENT AG, its | ||
|
General Partner | ||
|
| ||
|
| ||
|
By: |
/s/ RICE POWELL | |
|
|
Name: |
Rice Powell |
|
|
Title: |
Chief Executive Officer and Chairman of the Management Board of the General Partner |
|
|
|
|
|
|
|
|
|
By: |
/s/ MICHAEL BROSNAN | |
|
|
Name: |
Michael Brosnan |
|
|
Title: |
Chief Financial Officer and Member of the Management Board of the General Partner |
Ad-hoc announcement according |
Media Contact |
to Art. 17 (1) MAR |
Matthias Link |
|
T +49 6172 609-2872 |
|
matthias.link@fresenius.com |
|
|
|
Contact for analysts and investors |
|
Dr. Dominik Heger |
|
T +49 6172 609-2601 |
|
dominik.heger@fmc-ag.com |
|
|
|
www.freseniusmedicalcare.com |
February 20, 2019
Fresenius Medical Care resolves share repurchase program with an aggregate volume of up to one billion Euros
Fresenius Medical Care, the worlds largest provider of dialysis products and services, has resolved to repurchase shares of the Company with an aggregate volume of up to one billion Euros via the capital markets over the next two years.
The share repurchase program will be carried out in several tranches and in accordance with the EU safe harbor provisions. Further details will be disclosed prior to the start of the share repurchase program.
Person making the notification:
Dr. Dominik Heger
SVP Investor Relations & Corporate Communications
Fresenius Medical Care is the worlds largest provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,928 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 333,331 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Companys website at www.freseniusmedicalcare.com.